Brian Avanzino is Director of Discovery Research at Rondo Therapeutics where he leads teams focused on the discovery and development of novel multispecific antibodies for the treatment of solid tumors. Previously, he was at Amgen and Teneobio where he led and advanced several T cell engager programs through different stages of research and development including target validation, lead discovery, lead optimization and preclinical studies. Brian holds a PhD in Biochemistry and Molecular Biology and a BS in Biological Sciences from the University of California, Davis.